Contineum Therapeutics (Contineum Therapeutics) EV-to-Revenue : (As of May. 25, 2024)

Contineum Therapeutics EV-to-Revenue Chart

Competitive Comparison of Contineum Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Contineum Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's EV-to-Revenue falls into.

Contineum Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Contineum Therapeutics's EV-to-Revenue for today is calculated as:

Contineum Therapeutics's current Enterprise Value is $297.08 Mil.
Contineum Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics  (NAS:CTNM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Contineum Therapeutics's PS Ratiofor today is calculated as:

Contineum Therapeutics's share price for today is $15.76.
Contineum Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description